Gilead Sciences (GILD) Convertible Debt (2009 - 2010)
Gilead Sciences' (GILD) quarterly Convertible Debt came in at $2.8 billion in Q4 2010, up 145.67% on a YoY basis from $1.2 billion in Q4 2009, and up 0.7% quarter-over-quarter from $2.8 billion in Q3 2010.
Powered by 
Analysis
Gilead Sciences (GILD) Convertible Debt (2009 - 2010) Analysis & Trends
Gilead Sciences (GILD) has reported Convertible Debt for 2 consecutive years, with $2.8 billion the latest figure, recorded in Q4 2010.
- For the quarter ending Q4 2010, Convertible Debt rose 145.67% year-over-year to $2.8 billion; the trailing twelve-month figure through Dec 2010 stood at $2.8 billion (up 145.67% YoY), and the FY2010 full-year result was $2.8 billion, up 145.67% from the prior year.
- Convertible Debt advanced to $2.8 billion in Q4 2010 per GILD's latest filing, from $2.8 billion in the prior quarter.
- Across five years, Convertible Debt topped out at $2.8 billion in Q4 2010 and bottomed at $1.1 billion in Q2 2009.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2010 | 2.84 Bn |
| Sep 30, 2010 | 2.82 Bn |
| Mar 31, 2010 | 1.17 Bn |
| Dec 31, 2009 | 1.16 Bn |
| Sep 30, 2009 | 1.14 Bn |
| Jun 30, 2009 | 1.13 Bn |